Archived webinar.
Training slides review potential ARV drug-drug interactions and identify resources for the evaluation of drug-drug interactions.
Training slides learning objectives include:
Training slides learning objections include:
The National HIV Curriculum (NHC) provides free, up-to-date content for healthcare professionals to learn about HIV diagnosis, treatment, and preventi...
This training slide presents updated data long acting injectable (LAI) cabotegravir/rilpivirine for treatment. Differentiate monitoring st...
This training presentation will compare factors that affect medication adherence and apply a patient centered approach to ART adherence.
This presentation lists strategies that reduce the risk of meningitis in people with HIV. Demonstrates how to recognize clinical symptoms...
These slide sets describe the effects of aging on pharmacokinetic and pharmacodynamic parameters, avoiding drug adverse effects, as well as management...
These slides provide basic information on Dolutegravir-Rilpivirine, an antiretroviral therapy (ART) treatment, including key drug interactions and stu...
These slides provide information on causes of creatinine elevation in people with HIV (PWH), workup of creatinine elevation, as well as the effects of...
These guideline slides provide information and recommendations on statin therapy as primary prevention for cardiovascular disease. Antiret...
This recorded webinar, summarizes the pharmacologic action and effectiveness, as well as the appropriateness of HIV treatment with cabotegravir/rilpiv...
The popular AETC Program no-cost app supports health care providers with point-of-care tools for HIV screening, prevention, and care.
Comprehensive guidelines, including:
Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center
An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate renal impairment (estimated glomerula...
Coauthor: Susa Coffey, MD; Medical Editor, AETC National Resource Center
Treatment of dyslipidemia is often complicated by drug interactions between statins and antiretrovirals. Pitavastatin is one of the newer statins approved and is one of the few that is not metabolized primarily by the CYP450 3A4...
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and deat...
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg with b...
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted darunavir du...
